How current maintenance therapy is changing in ovarian cancer and what’s next

Video Transcription

Video Summary

In this webinar, the panelists discuss the changing landscape of maintenance therapy in ovarian cancer treatment. They start by presenting the results of a poll which asked attendees about their preferred maintenance strategies in first-line treatment. The majority of respondents chose PARP inhibitors as the main strategy, followed by a combination of PARP and Bevacizumab. They also discuss the options for maintenance therapy in a patient who experienced recurrence after platinum-based chemotherapy. The panelists agree that reintroducing a PARP inhibitor in this situation is not supported by the evidence, as patients who progress on PARP inhibitors develop mechanisms that limit the efficacy of a second exposure. They also highlight the importance of clinical trials, with one panelist mentioning a trial using an antibody-drug conjugate targeting the folate receptor. The panelists then discuss the preferred maintenance strategy in an HRP patient, with a debate between using Bevacizumab or PARP inhibitors. They note that regulatory restrictions may play a role in the available options and emphasize the need for further data to guide treatment decisions. Overall, the panelists stress the importance of individualizing treatment based on the patient's characteristics and considering the available evidence and clinical trial options.

Keywords

webinar

maintenance therapy

ovarian cancer treatment

PARP inhibitors

Bevacizumab

recurrence

platinum-based chemotherapy